Helix BioPharma to Acquire Laevoroc’s Oncology Assets

Helix BioPharma (TSE:HBP) has released an update.

Helix BioPharma Corp. has entered into a non-binding letter of intent to acquire the oncology assets of Laevoroc Group, potentially enhancing their immuno-oncology portfolio. The acquisition includes a novel oral chemotherapy formulation and a preclinical immune checkpoint inhibitor, which could simplify cancer treatment and offer new hope for leukemia patients.

For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.